DrugPatentWatch Database Preview
RUBRACA Drug Profile
When do Rubraca patents expire, and what generic alternatives are available?
Rubraca is a drug marketed by Clovis Oncology Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has two hundred and thirty-six patent family members in fifty-two countries.
The generic ingredient in RUBRACA is rucaparib camsylate. One supplier is listed for this compound. Additional details are available on the rucaparib camsylate profile page.
Summary for RUBRACA
| International Patents: | 236 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 41 |
| Clinical Trials: | 7 |
| Patent Applications: | 45 |
| Drug Prices: | Drug price information for RUBRACA |
| DailyMed Link: | RUBRACA at DailyMed |
Generic Entry Opportunity Date for RUBRACA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for RUBRACA
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
Synonyms for RUBRACA
| 283173-50-2 |
| 6-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-3,10-DIAZATRICYCLO[6.4.1.0?,(1)(3)]TRIDECA-1,4(13),5,7-TETRAEN-9-ONE |
| 6H-Azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)- |
| 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)- |
| 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]- |
| 8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON |
| 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one |
| 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one |
| 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE |
| 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one |
| 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
| 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
| 8237F3U7EH |
| AC-24390 |
| AG 014699 |
| AG-14447 |
| AG14447 |
| AK317822 |
| AKOS015898427 |
| BDBM50446130 |
| BRD-K88560311-011-01-4 |
| CHEBI:134689 |
| CHEBI:94311 |
| CHEMBL1173055 |
| CS-2785 |
| CTK4G1217 |
| D01SHZ |
| D10079 |
| DB12332 |
| DTXSID10182563 |
| FT-0696622 |
| GTPL7736 |
| HMABYWSNWIZPAG-UHFFFAOYSA-N |
| HY-10617A |
| I10-0690 |
| KB-73984 |
| Kinome_3180 |
| MolPort-028-744-762 |
| NCGC00263173-01 |
| NCGC00263173-03 |
| PF 01367338 |
| PF01367338 |
| PL006099 |
| RPB |
| Rubraca (TN) |
| RUCAPARIB |
| Rucaparib (free base) |
| Rucaparib (USAN/INN) |
| Rucaparib [USAN:INN] |
| Rucaparib(AG-014447) |
| SCHEMBL844585 |
| Tube725 |
| UNII-8237F3U7EH |
| Z-3241 |
| ZINC25958 |
US Patents and Regulatory Information for RUBRACA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for RUBRACA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Georgia, Republic of | P20033055 | ➤ Sign Up |
| Australia | 2004220321 | ➤ Sign Up |
| South Korea | 101138471 | ➤ Sign Up |
| Eurasian Patent Organization | 200501434 | ➤ Sign Up |
| Japan | 2008001718 | ➤ Sign Up |
| United Kingdom | 2419882 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for RUBRACA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015016,C1633724 | Lithuania | ➤ Sign Up | PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
| 0150012 00136 | Estonia | ➤ Sign Up | PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014 |
| 500012 | Hungary | ➤ Sign Up | PRODUCT NAME: OLAPARIB |
| 2015 00012 | Denmark | ➤ Sign Up | PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216 |
| C0022 | France | ➤ Sign Up | PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218 |
| 90019-4 | Sweden | ➤ Sign Up | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
